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1150 Abstracts October 2013Table. Multivariate model: Vascular 30-day readmissions
Covariate OR 95% CI P valueBlack/African American (ref ¼ white) 1.21 1.04-1.41 .014
Procedure (ref ¼ carotid) Ref Ref <.001
EVAR 1.06 0.85-1.32 .616
Open AAA 1.53 1.18-1.98 .001
Other 1.49 1.24-1.80 <.001
Peripheral 1.93 1.59-2.34 <.001
Amputation 1.24 0.99-1.53 .057
Disposition (reference ¼ home) Ref Ref <.001
Nursing facility (prior) 1.54 1.13-2.10 .007
Facility/rehab (new) 1.30 1.12-1.50 <.001
Hypoalbuminemia 1.35 1.18-1.55 <.001
Pulmonary comorbidity 1.35 1.17-1.56 <.001
Cardiac comorbidity 1.28 1.13-1.44 <.001
Renal comorbidity 1.24 1.02-1.50 .033
VTE prior to discharge 1.83 1.00-3.36 .050
Graft failure prior to discharge 2.07 1.03-4.134 .040Scientiﬁc Session III: Peripheral
Risk Factors for Below-the-Knee Amputation Failure Requiring
Above-the-Knee Revision
Wadi Gomero-Cure, John J. Ricotta, Susanna Shin, Fred Beavers, Cameron
Akbari, Paul Foley. Washington Hospital Center, D.C
Objectives: The purpose of this study was to identify risk factors that
impact below-the-knee (BKA) failures requiring proximal revision to an
above-the-knee amputation (AKA).
Methods: All consecutive major lower extremity amputations or revi-
sions in vascular patients between 2009 and 2010 were identiﬁed. Medical
records were retrospectively reviewed for patient demographics, comorbid-
ities, amputation level, wound-healing, survival, and anatomic data (from
angiography and duplex examinations). Patients who healed their BKA
were compared with those requiring a proximal revision to an AKA. Statistical
analysis was performed with SAS System 9.1.3 (SAS Institute Inc, Cary, NC).
Results: Major lower extremity amputations or revisions were per-
formed on 247 limbs in 218 patients (age 66.7 6 12.2 years, 51% male,
87% African American). BKA was performed on 157 limbs (64%) with heal-
ing achieved in 114 (73%) and failure to heal in 42 (27%), of which 26 BKAs
(17%) required revision to an AKA. Women (58% vs 35%; P < .05), patients
with rest pain (15.4% vs 2.8%; P < .05), history of cardiac intervention or
surgery (50% vs 27%; P < .05), lower pre-albumin (9.3 6 2.5 mg/dL vs
13.1 6 7.8 mg/dL; P < .05) and patients with dementia (19.2% vs 6.4%;
P < .05) were more likely to require BKA to AKA revision. Preoperative
angiographic data was available for 69 (60%) of the healed BKAs and 17
(65%) of the BKA to AKA revisions. Ipsilateral common iliac artery stenosis
greater than 50% (18% vs 1.5%; P < .05), superﬁcial femoral artery occlusion
(70% vs 23%; P < .05), popliteal artery occlusion (47.1% vs 14.5%; P < .05)
and the combination of popliteal occlusion with no tibial runoff (29.4% vs
4.4%, P < .05) were each associated with BKA failures. Arterial duplex
data was available for 32 (28%) of the healed BKAs and six (23%) of the
BKAs to AKA revisions. Peak systolic velocities were signiﬁcantly lower
and below normal thresholds in the BKA failures at the external iliac artery
(P < .05), common femoral artery (P < .05), distal superﬁcial femoral artery
(P < .05), and popliteal artery (P < .05). Median survival was not signiﬁ-
cantly different between the two groups (4.0 vs 3.1 years).
Conclusions: Patients requiring a BKA to AKA revision have identiﬁ-
able risk factors that could be used to predict healing at a particular level and
obviate additional morbidity from subsequent revisions. Long-term survival
does not appear to be negatively impacted by amputation revisions.
Cilostazol Is Associated with Improved Outcomes after Peripheral
Endovascular Interventions: A Meta-Analysis
Courtney J. Warnera, Spencer W. Greavesb, Robin J. Larsonb, Randall R. De
Martinoa, Richard J. Powella, Daniel B. Walsha, Philip P. Goodneya.
aDartmouth-Hitchcock Medical Center, Lebanon, NH; bThe Dartmouth
Institute, Lebanon, NH
Objectives: While cilostazol is commonly used as an adjunct
following peripheral vascular interventions (PVI), its efﬁcacy remains uncer-
tain. We assessed the effect of cilostazol on outcomes following PVI using
meta-analytic techniques.Methods: We searched MEDLINE (1946-2012), Cochrane
CENTRAL (1996-2012), and trial registries for studies comparing cilosta-
zol in combination with antiplatelet therapy to antiplatelet therapy alone
following PVI. Treatment effects were reported as pooled risk/hazard ratios
using random effects models.
Results: Two randomized trials and four retrospective cohort studies
met inclusion criteria (total n ¼ 1522). Across studies, mean age ranged
from 66-76 years, the majority of patients were male (59%-82%), and
mean follow-up ranged from 18-37 months. Pooled estimates demonstrated
that the addition of cilostazol was associated with decreased restenosis (RR,
0.71; 95% CI, 0.60-0.84; P < .001,), improved amputation-free survival
(HR, 0.63; 95% CI, 0.47-0.85; P ¼ .002), improved limb salvage (HR,
0.42; 95% CI, 0.27-0.66; P < .001), and improved freedom from target
lesion revascularization (RR, 1.36; 95% CI, 1.14-1.61; P < .001) (Fig).
There was no signiﬁcant reduction in mortality among those receiving cil-
ostazol (RR, 0.73; 95% CI, 0.45-1.19; P ¼ .21).
Conclusions: The addition of cilostazol to standard therapy following
PVI is associated with a reduced risk of restenosis, amputation and target
lesion revascularization in our meta-analysis of six studies. Consideration
of cilostazol as a medical adjunct after PVI is warranted, presuming these
ﬁndings are broadly generalizable.
Fig.
Contemporary Outcomes of Endovascular vs Surgical Revascula-
rization for Acute Limb Ischemia (ALI)
Ashraf Taha, Efthimios Avgerinos, Luke Marone, Raphael Byrne, Larry
Fish, Michel Makaroun, Rabih A. Chaer. UPMC, Pittsburgh, Pa
Objectives: The purpose of this study was to compare contemporary
endovascular with surgical revascularization for ALI.
Methods: Consecutive patients with ALI treated with endovascular
(ER) or surgical revascularization (OR) between 2005 and 2011 were
identiﬁed and reviewed. Procedural success and outcomes were com-
pared between the two groups. Limb salvage and survival were assessed
using time-to-event methods, including Kaplan-Meier estimation and
competing-risks regression models.
Results: One-hundred ﬁfty-four limbs were treated in 147 patients
in the ER group, compared with 330 limbs in 296 patients in the OR
group. Patient characteristics, severity of ischemia, and indications for
intervention are presented in the Table. The mean follow-up was 14
months. Overall technical success was achieved in 80.5% (ER) vs 88.6%
(OR) (P ¼ .019). Thirty-day mortality rate was 5.4% (ER) and 13.2%
(OR) (P ¼ .013). Amputation rates were 6.5% (ER) vs13.3% (OR) at 30
days (P ¼ .027), and 13.0% (ER) and 19.7% (OR) at 1 year (P ¼ .075).
The primary patency was 57% (ER) and 53% (OR) at 1 year (P ¼ .301).
Rutherford class 2 ischemia represented the majority of our patients,
where overall technical success was 79.9% (ER) vs 91.5% (OR) (P ¼ .001).
Technical success in this class was higher with OR when performed for
a failed bypass (94.7% OR vs 75% ER; P ¼ .001), but with similar 1-year
amputation rates (25.0% OR vs 23.1% ER; P ¼ .84). Technical success was
comparable between the two groups for patients treated for embolic ALI
or in situ thrombosis, as were the amputation rates at 30 days and 1 year (P
¼ NS). Predictors of limb loss by life table analysis included coronary
artery disease (SHR ¼ 2.24; P ¼ .005) and end stage renal disease/dialysis
(SHR ¼ 2.76; P ¼ .031). Predictors of death by life table analysis included
age (SHR ¼ 1.02; P ¼ .001), end-stage renal disease (SHR ¼ 5.67; P <
.001), cancer (SHR ¼ 1.48; P ¼ .02), and rhabdomyolysis (SHR ¼ 3.07;
P < .01).
Conclusions: Patients presenting with Rutherford class 2 ALI are
commonly treated with endovascular or surgical revascularization with
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technical success is higher with open revascularization for patients present-
ing with failed bypass grafts, the amputation rates are comparable. Mortality





group, No. (%) P value
Smoking
<.001No 151 (51.4) 37 (25.5)
Former 49 (16.7) 42 (29.0)
Current 94 (32.0 66 (45.5)
Comorbidities
Coronary artery disease 144 (48.8) 79 (55.2) .21
End-stage renal disease/dialysis 12 (4.1) 6 (4.2) .95
Congestive heart failure 57 (19.3) 28 (19.6) .95
Chronic obstructive pulmonary 86 (29.2) 33 (23.1) .18
disease
Atrial ﬁbrillation 114 (38.6) 32 (22.4) .001
Chronic renal insufﬁciency 39 (13.2) 31 (22.0) .02
Diabetes 91 (30.9) 57 (40.1) .06
Cause of ischemia
Cardiac embolism 85 (27.1) 14 (9.1) <.001
Native artery thrombosis 103 (32.8) 37 (24) .05
Failed stent 32 (10.1) 41 (26.6) <.001
Failed bypass 98 (31.0) 56 (36.4) .25
Thrombosed peripheral
aneurysm
18 (5.7) 6 (3.9) .41
Aortoiliac embolism 13 (4.1) 8 (5.2) .61
Distribution by severity
Rutherford I 4 (1.27) 15 (9.74)
Rutherford IIa 127 (40.19) 108 (70.13)
Rutherford IIb 132 (41.77) 31 (20.13)
Rutherford III 13 (4.11) 0 (0)Protective Effects of Angiotensin Ii Type-1 Receptor Blockade With
Olmesartan On Spinal Cord Ischemia-Reperfusion Injury: An
Experimental Study on Rats
Adem Gulera, Mehmet Ali Sahina, Fahri Gurkan Yesila, Alper Ucakb, Burak
Onanc, Kaan Inanb, Emin Oztasb, Sıddık Arsland, Bulent Uysala, Ufuk
Demirkilica, Harun Tatara. aGulhane School of Medicine, Ankara, Turkey;
bGulhane School of Medicine, Istanbul, Turkey; cMehmet Akif Ersoy
Hospital, Istanbul, Turkey; dGazi University Hospital, Ankara, Turkey
Objectives: Spinal cord injury is a major complication of thoracoab-
dominal aortic operations. We aimed to investigate neuroprotective role
of olmesartan administered to rats before ischemia against ischemia-reperfu-
sion (I-R) injury.
Methods: Twenty-four Wistar albino rats were randomly divided into
three groups (n ¼ 8 per group): group I (control group, the sham-operation
group), group II (the I-R group undergoing aortic occlusion without phar-
macologic treatment), and group III (olmesartan-treated group receiving 3
mg/kg/d olmesartan for 14 days before ischemia). Spinal cord ischemia was
induced by infrarenal aortic clamping for 45 minutes, followed by reperfu-
sion. Neurologic status was assessed by using modiﬁed Tarlov score preop-
eratively and at 48 hours postoperatively. Spinal cords were harvested for
histopathologic examination with hematoxylin-eosin staining and biochem-
ical analysis for tissue malondialdehyde, superoxide dismutase, and gluta-
thione peroxidase levels.
Results: The rats in the ischemia group had severe deﬁcits including
paraplegia after surgery, and they had a worse neurologic status compared
with the sham group (P < .05). The mean Tarlov scores in the ischemia
and olmesartan-treated groups at 48 hours postoperatively were 1.6 6
0.4 and 2.2 6 0.9, respectively (P < .05). Histopathologic analyses
demonstrated typical changes of ischemic necrosis in the ischemia group;
however, olmesartan attenuated tissue necrosis. Decreased spinal cord
tissue malondialdehyde (P ¼ .047) and increased tissue superoxide dismu-
tase (P ¼ .001) and glutathione peroxidase (P ¼ .009) levels were
measured in the olmesartan-treated group compared with the ischemia
group.
Conclusions: Olmesartan may protect the spinal cord from I-R injury
and reduce the incidence of associated neurological dysfunction after
temporary aortic occlusion.Impact of Chronic Kidney Disease on the Effectiveness of Peripheral
Endovascular Interventions
Heather L. Gill, Jeffrey J. Siracuse, Peter H. Connolly, John K. Karwowski,
Harry L. Bush, Darren B. Schneider, Andrew J. Meltzer. Weill Cornell
Medical College, New York, NY
Objectives: Patients with severe chronic kidney disease (CKD) were
excluded from the Society for Vascular Surgery objective performance goals
(OPG) derivation cohort due to established poor surgical outcomes in this
group. We examine the impact of diminished creatinine clearance (CrCl) on
the long-term outcomes of peripheral endovascular interventions.
Methods: Retrospective review of prospectively collected institutional
outcomes data (2006-2012) included calculation of CrCl and stratiﬁcation
by CKD class. Outcomes among those with mild (class 1, 2) moderate (class
3), and severe (class 4, 5) CKD were compared using Society for Vascular
Surgery OPG outcome metrics. Multivariate models were developed to iden-
tify risk factors for poor outcome and speciﬁcally assess the impact of CKD.
Results: 454 patients underwent treatment of 523 limbs for claudica-
tion (56%), rest pain (12%), or tissue loss (32%). Over 77% of patients had
abnormally low CrCl, with moderate CKD noted in 37% and severe CKD in
13%. Increasing CKD class was associated with worse outcomes across all
outcome metrics by crude survival analysis. Following adjustment for all
other risk factors, the impact of severe CKD was independently associated
with reduced overall survival (HR, 2.69; 95% CI, 1.70-4.26; P < .001),
amputation-free survival (HR, 3.15; 95% CI, 2.04-3.86; P < .001), limb
salvage (HR, 4.35; 95% CI, 1.50-12.33; P ¼ .006), major adverse limb
events (HR, 2.07; 95% CI, 1.02-4.20; P ¼ .04), freedom from reinterven-
tion and amputation (HR, 1.82; 95% CI, 1.12-2.94; P ¼ .015), and
freedom from reintervention, amputation, and stenosis (HR, 1.58; 95%
CI, 1.02-2.46; P ¼ .041).
Conclusions: Moderate and severe CKD are highly prevalent among
patients with peripheral artery disease. While severe CKD adversely affects
long-term outcomes after ET as well as surgical bypass, quantiﬁcation of
the impact of reduced CrCl on survival- and limb-based metrics may
enhance risk adjustment for comparative effectiveness research and improve
patient-centered clinical decision-making.
Lower Extremity Bypass for Critical Limb Ischemia-Predicting
Extended Length of Stay
Jeffrey J. Siracuse, Douglas W. Jones, Heather L. Gill, Ashley Graham,
Darren B. Schneider, Harry L. Bush, John K. Karwowski, Peter H.
Connolly, Andrew J. Meltzer. Weill Cornell Medical Center, New York, NY
Objectives: Inpatient hospital length of stay (LOS) is a metric that is
increasingly associated with healthcare efﬁciency and quality. Infrainguinal
bypass has traditionally been associated with a long postoperative LOS.
We sought to identify preoperative risk factors for protracted postoperative
LOS after lower extremity bypass for critical limb ischemia (CLI) to better
anticipate those at risk while in the preoperative phase.
Methods: Patient data from the 2007-2009 American College of
Surgeons National Surgical Quality Improvement Program were used to
develop a speciﬁc database consisting of patients undergoing bypass surgery
for CLI (n ¼ 4894). Protracted postoperative LOS was deﬁned as the top
quartile of duration of hospitalization days from surgery until discharge.
Over 50 preoperative, procedural, and postoperative variables were tested
for association. Risk factors with signiﬁcant association (Pearson c2, P <
.05) were used to develop a logistic regression model for protracted postop-
erative LOS.
Results: Average postoperative LOS was 7.5 days (median, 6 days).
The top quartile of postoperative LOS >8 days, was used to deﬁne pro-
tracted LOS. Independent risk factors for protracted postoperative LOS
included distal bypass target (OR, 1.6; 95% CI, 1.4-1.8), non-Caucasian
race (OR, 1.67; 95% CI, 1.4-1.9), obesity (OR, 1.3; 95% CI, 1.1-1.5),
partial functional dependence (OR, 2.0; 95% CI, 1.7-2.3), complete func-
tional dependence (OR, 2.8; 95% CI, 1.8-4.3), history of cardiac disease
(OR, 1.5; 95% CI, 1.1-2.0), history of peripheral vascular interventions
(OR, 1.3; 95% CI, 1.1-1.5), bleeding disorders (OR, 1.2; 95% CI, 1.03-
1.4), emergency operation (OR, 1.9; 95% CI, 1.4-2.7), age greater than
80 (OR, 1.45; 95% CI, 1.3-1.7), tissue loss (OR, 1.9; 95% CI, 1.6-2.3),
extended preoperative hospitalization (OR, 2.2; 95% CI, 1.8-2.6), and dial-
ysis dependence (OR, 1.6; 95% CI, 1.3-2.0).
Conclusions: LOS has received signiﬁcant attention in the context of
the current healthcare climate and the Affordable Care Act. Here, we iden-
tify risk factors for protracted postoperative LOS after surgical bypass for
CLI, a metric of speciﬁc importance to vascular surgeons. These ﬁndings
provide important evidence for the ongoing dialogue regarding efforts to
reduce LOS. Here, we can identify patients early in the preoperative period
that may be at risk for increased LOS allowing early multidisciplinary inter-
vention with other medical and social services.
